A5078629724- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Advanced Radiotherapy Techniques
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Brain Metastases and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Statistical Methods in Clinical Trials
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Head and Neck Cancer Studies
- Economic and Financial Impacts of Cancer
Florida Hospital Cancer Institute
2016-2025
University of Pittsburgh
2008-2025
AdventHealth Orlando
2020-2024
University of North Carolina at Chapel Hill
2006-2023
UNC Lineberger Comprehensive Cancer Center
2005-2023
University of Pittsburgh Medical Center
2012-2023
Segeberger Kliniken
2023
Weatherford College
2023
Cancer Institute (WIA)
2020-2022
AdventHealth Tampa
2020-2022
The cancer-cell-killing property of atezolizumab may be enhanced by the blockade vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated plus bevacizumab chemotherapy in patients metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.We randomly assigned to receive carboplatin paclitaxel (ACP), (BCP), or BCP (ABCP) every weeks for four six cycles, followed maintenance therapy...
Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed perform multiplexed assays testing adenocarcinomas for in 10 genes enable clinicians select targeted treatments enroll into clinical trials.To determine frequency use data targeting identified driver(s) measure survival.From 2009 through 2012, 14 sites United States enrolled metastatic a...
This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based (sb-paclitaxel) in advanced non-small-cell lung cancer (NSCLC).In all, 1,052 untreated patients stage IIIB to IV NSCLC were randomly assigned 1:1 receive 100 mg/m(2) nab-paclitaxel weekly at area under concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 sb-paclitaxel AUC (sb-PC). The primary end point was objective overall response rate...
An increase in the dose of chemotherapy enhances response many experimental and clinical cancers, but extent escalation is often limited by myelosuppression. In preliminary trials, recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) has augmented leukocyte numbers function, optimal not established. We treated 16 adults who had inoperable or metastatic sarcomas with escalating doses rhGM-CSF before immediately after a first cycle (cycle 1) to assess hematologic...
Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated platinum-based chemotherapy in stage IV squamous NSCLC.A total of 1021 patients were 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) 343), or carboplatin+nab-paclitaxel (CnP) 340) four six 21-day...
Purpose The significance of radiotherapy (RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study. We assessed impact dose patients treated at our institution on several prospective dose-escalation trials. Patients and Methods From 1996 to 2009, 127 NSCLC (Eastern Cooperative performance status, 0 1) received dose-escalated RT 70 90...
PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy safety pemetrexed (Pem) plus carboplatin (C) bevacizumab (Bev) followed by (PemCBev) with paclitaxel (Pac) (PacCBev) patients advanced nonsquamous non-small-cell lung cancer (NSCLC).
IntroductionWe report the final results of phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin pemetrexed (APP) in patients with nonsquamous NSCLC.MethodsChemotherapy-naive stage IV NSCLC without sensitizing EGFR ALK genetic alterations were randomized a one-to-one ratio to receive four six cycles (PP) APP every weeks, followed by maintenance therapy alone. Co-primary end points overall survival (OS) and investigator-assessed progression-free (PFS).ResultsThe...
IntroductionWe report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months median follow-up atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) in chemotherapy-naive patients metastatic nonsquamous NSCLC phase 3 IMpower150 study (NCT02366143).MethodsIn this randomized, open-label (N = 1202), coprimary end points included investigator-assessed...
Aberrant vascular endothelial growth factor (VEGF) and platelet-derived (PDGF) signaling have been shown to play a role in non-small-cell lung cancer (NSCLC) pathogenesis are associated with decreased survival. We evaluated the clinical activity tolerability of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks receptors for VEGF PDGF, as well related kinases patients previously treated, advanced NSCLC.
Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) phase trials. This III trial compared the safety efficacy of amrubicin versus topotecan as second-line treatment for SCLC.A total 637 patients with refractory or sensitive SCLC were randomly assigned at ratio 2:1 to 21-day cycles 40 mg/m(2) intravenously (IV) on days 1 3 1.5 IV 5. Primary end point was overall survival (OS); secondary points included...
Lung squamous cell carcinoma (SCC) is clinically and genetically heterogeneous, current diagnostic practices do not adequately substratify this heterogeneity. A robust, biologically based SCC subclassification may describe variability lead to more precise patient prognosis management. We sought determine if mRNA expression subtypes exist, are reproducible across multiple cohorts, relevant.Subtypes were detected by unsupervised consensus clustering in five published discovery cohorts of...
Background Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well understood, limiting progress in therapy development and research. LAD intrinsic molecular subtypes are a validated stratification of naturally-occurring gene expression patterns encompass different functional pathways patient outcomes. Patients may have incurred mutations alterations that led to the subtypes. We hypothesized co-occur with distinct tumors. Methodology/Principal...
8001 Background: c-Met-amplified NSCLC defines a subset of that may be sensitive to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for treatment advanced ALK-positive NSCLC. Efficacy and safety data are presented crizotinib in patients with within 3 categories amplification MET/CEP7 ratio ≥1.8-≤2.2 (Low), >2.2-<5 (Intermediate) ≥5 (High). Methods: c-METamplification status was determined by FISH, 10-12 enrolled into each category. If 2 or more objective...
Erlotinib is clinically effective in patients with non-small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, EGFR mutant tumors. We investigated the efficacy of erlotinib alone combination chemotherapy these characteristics.
LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor histology. Because cytotoxic agents can exhibit positive immunomodulatory effects, combining atezo with chemotherapy may further improve outcomes. IMpower131 (NCT02367794) was designed to evaluate + carboplatin (carbo) paclitaxel (pac) nab-paclitaxel (nab-pac) 1L stage IV squamous NSCLC. Methods: Patients (pts) were randomized 1:1:1 Arm A (atezo 1200 mg...